1
|
Binefa G, Rodríguez-Moranta F, Teule A and
Medina-Hayas M: Colorectal cancer: From prevention to personalized
medicine. World J Gastroenterol. 20:6786–6808. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Guariguata L, Whiting DR, Hambleton I,
Beagley J, Linnenkamp U and Shaw JE: Global estimates of diabetes
prevalence for 2013 and projections for 2035. Diabetes Res Clin
Pract. 103:137–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Renehan AG, Yeh HC, Johnson JA, Wild SH,
Gale EA and Møller H; Diabetes and cancer research consortium, :
Diabetes and cancer (2): Evaluating the impact of diabetes on
mortality in patients with cancer. Diabetologia. 55:1619–1632.
2012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Johnson JA, Carstensen B, Witte D, Bowker
SL, Lipscombe L and Renehan AG; Diabetes and cancer research
consortium, : Diabetes and cancer: Evaluating the temporal
relationship between type 2 diabetes and cancer incidence.
Diabetologia. 55:1607–1618. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Park HK: Metformin and cancer in type 2
diabetes. Diabetes Metab J. 37:113–116. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Din FV, Valanciute A, Houde VP, Zibrova D,
Green KA, Sakamoto K, Alessi DR and Dunlop MG: Aspirin inhibits
mTOR signaling, activates AMP-activated protein kinase, and induces
autophagy in colorectal cancer cells. Gastroenterology.
142:1504–1515 e3. 2012. View Article : Google Scholar : PubMed/NCBI
|
7
|
O'Brien AJ, Villani LA, Broadfield LA,
Houde VP, Galic S, Blandino G, Kemp BE, Tsakiridis T, Muti P and
Steinberg GR: Salicylate activates AMPK and synergizes with
metformin to reduce the survival of prostate and lung cancer cells
ex vivo through inhibition of de novo lipogenesis. Biochem J.
469:177–187. 2015. View Article : Google Scholar : PubMed/NCBI
|
8
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual.
Springer-Verlag; New York: 2010
|
9
|
American Diabetes Association, . Diagnosis
and classification of diabetes mellitus. Diabetes Care. 37 Suppl
1:S81–S90. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Word Health Organization, . ICD-10
International statistical classification of diseases and related
health problems. World Health Organization; Geneva: 2011
|
11
|
Armitage P and Berry G: Statistical
methods in medical research. 2nd. Oxford, Boston, Blackwell
Scientific, Chicago, III, Distributors, USA: Year Book Medical
Publishers, England; 1987
|
12
|
Kalbfleisch JD and Prentice RL: The
statistical analysis of failure time data. John Wiley; New York:
1980
|
13
|
Grambsch PM and Therneau TM: Proportional
hazards tests and diagnostics based on weighted residuals.
Biometrika. 81:515–526. 1994. View Article : Google Scholar
|
14
|
Estève J, Benhamou E and Raymond L:
Statistical methods in cancer research. Volume IV. Descriptive
epidemiology. IARC Sci Publ. 1994:3021994.
|
15
|
Ederer F, Axtell LM and Cutler SJ: The
relative survival rate: A statistical methodology. Natl Cancer Inst
Monogr. 6:101–121. 1961.PubMed/NCBI
|
16
|
Patruno V, Venturi M and Roberto S:
Demografia in cifre-Tavole di Mortalità. Available from ISTAT.
http://www.demo.istat.it/tvm2016
|
17
|
Breslow NE and Day NE: Statistical methods
in cancer research. Volume II-The design and analysis of cohort
studies. IARC Sci Publ. 1–406. 1987.
|
18
|
Cuzick J: A Wilcoxon-type test for trend.
Stat Med. 4:87–90. 1985. View Article : Google Scholar : PubMed/NCBI
|
19
|
Rosato V, Tavani A, Gracia-Lavedan E,
Guinó E, Castaño-Vinyals G, Villanueva CM, Kogevinas M, Polesel J,
Serraino D, Pisa FE, et al: Type 2 diabetes, antidiabetic
medications and colorectal cancer risk: Two case-control studies
from italy and spain. Front Oncol. 6:2102016. View Article : Google Scholar : PubMed/NCBI
|
20
|
Siddiqui AA, Spechler SJ, Huerta S, Dredar
S, Little BB and Cryer B: Elevated HbA1c is an independent
predictor of aggressive clinical behavior in patients with
colorectal cancer: A case-control study. Dig Dis Sci. 53:2486–2494.
2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Campbell PT: The role of diabetes and
diabetes treatments in colorectal cancer mortality, incidence and
survival. Curr Nutr Rep. 2:37–47. 2013. View Article : Google Scholar
|
22
|
Peeters PJ, Bazelier MT, Leufkens HG, de
Vries F and De Bruin ML: The risk of colorectal cancer in patients
with type 2 diabetes: Associations with treatment stage and
obesity. Diabetes Care. 38:495–502. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Vergès B: Pathophysiology of diabetic
dyslipidaemia: Where are we? Diabetologia. 58:886–899. 2015.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Sirtori CR, Calabresi L, Pisciotta L,
Cattin L, Pauciullo P, Montagnani M, Manzato E, Bittolo Bon G and
Fellin R: Effect of statins on LDL particle size in patients with
familial combined hyperlipidemia: A comparison between atorvastatin
and pravastatin. Nutr Metab Cardiovasc Dis. 15:47–55. 2005.
View Article : Google Scholar : PubMed/NCBI
|
25
|
van Diepen JA, Vroegrijk IO, Berbée JF,
Shoelson SE, Romijn JA, Havekes LM, Rensen PC and Voshol PJ:
Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride
production in mice fed a high-fat diet. Am J Physiol Endocrinol
Metab. 301:E1099–E1107. 2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Yang G, Wang Y, Feng J, Liu Y, Wang T,
Zhao M, Ye L and Zhang X: Aspirin suppresses the abnormal lipid
metabolism in liver cancer cells via disrupting an NFκB-ACSL1
signaling. Biochem Biophys Res Commun. 486:827–832. 2017.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Eliasson B, Gudbjörnsdottir S, Zethelius
B, Eeg-Olofsson K and Cederholm J; National diabetes register
(NDR), : LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio
and risk for coronary heart disease in type 2 diabetes. Eur J Prev
Cardiol. 21:1420–1428. 2014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Middleton RJ, Foley RN, Hegarty J, Cheung
CM, McElduff P, Gibson JM, Kalra PA, O'Donoghue DJ and New JP: The
unrecognized prevalence of chronic kidney disease in diabetes.
Nephrol Dial Transplant. 21:88–92. 2006. View Article : Google Scholar : PubMed/NCBI
|
29
|
Dörhöfer L, Lammert A, Krane V, Gorski M,
Banas B, Wanner C, Krämer BK, Heid IM and Böger CA; DIACORE Study
Group, : Study design of DIACORE (DIAbetes COhoRtE) a cohort study
of patients with diabetes mellitus type 2. BMC Med Genet.
14:252013. View Article : Google Scholar : PubMed/NCBI
|
30
|
Casanova F, Adingupu DD, Adams F, Gooding
KM, Looker HC, Aizawa K, Dove F, Elyas S, Belch JJF, Gates PE, et
al: The impact of cardiovascular co-morbidities and duration of
diabetes on the association between microvascular function and
glycaemic control. Cardiovasc Diabetol. 16:1142017. View Article : Google Scholar : PubMed/NCBI
|
31
|
Notarnicola M, Altomare DF, Correale M,
Ruggieri E, D'Attoma B, Mastrosimini A, Guerra V and Caruso MG:
Serum lipid profile in colorectal cancer patients with and without
synchronous distant metastases. Oncology. 68:371–374. 2005.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Gomaraschi M, Ossoli A, Favari E, Adorni
MP, Sinagra G, Cattin L, Veglia F, Bernini F, Franceschini G and
Calabresi L: Inflammation impairs eNOS activation by HDL in
patients with acute coronary syndrome. Cardiovasc Res. 100:36–43.
2013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Din FV, Theodoratou E, Farrington SM,
Tenesa A, Barnetson RA, Cetnarskyj R, Stark L, Porteous ME,
Campbell H and Dunlop MG: Effect of aspirin and NSAIDs on risk and
survival from colorectal cancer. Gut. 59:1670–1679. 2010.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Sehdev A and O'Neil BH: The role of
aspirin, vitamin D, Exercise, diet, statins and metformin in the
prevention and treatment of colorectal cancer. Curr Treat Options
Oncol. 16:432015. View Article : Google Scholar : PubMed/NCBI
|
35
|
Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W,
Zhao G and Kip KE: Reduced risk of colorectal cancer with metformin
therapy in patients with type 2 diabetes: A meta-analysis. Diabetes
Care. 34:2323–2328. 2011. View Article : Google Scholar : PubMed/NCBI
|
36
|
Liu F, Yan L, Wang Z, Lu Y, Chu Y, Li X,
Liu Y, Rui D, Nie S and Xiang H: Metformin therapy and risk of
colorectal adenomas and colorectal cancer in type 2 diabetes
mellitus patients: A systematic review and meta-analysis.
Oncotarget. 8:16017–16026. 2017.PubMed/NCBI
|
37
|
Nie Z, Zhu H and Gu M: Reduced colorectal
cancer incidence in type 2 diabetic patients treated with
metformin: A meta-analysis. Pharm Biol. 54:2636–2642. 2016.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Mei ZB, Zhang ZJ, Liu CY, Liu Y, Cui A,
Liang ZL, Wang GH and Cui L: Survival benefits of metformin for
colorectal cancer patients with diabetes: A systematic review and
meta-analysis. PLoS One. 9:e918182014. View Article : Google Scholar : PubMed/NCBI
|
39
|
Du L, Wang M, Kang Y, Li B, Guo M, Cheng Z
and Bi C: Prognostic role of metformin intake in diabetic patients
with colorectal cancer: An updated qualitative evidence of cohort
studies. Oncotarget. 8:26448–26459. 2017.PubMed/NCBI
|
40
|
Ramjeesingh R, Orr C, Bricks CS, Hopman WM
and Hammad N: A retrospective study on the role of diabetes and
metformin in colorectal cancer disease survival. Curr Oncol.
23:e116–e122. 2016. View Article : Google Scholar : PubMed/NCBI
|
41
|
Zanders MM, van Herk-Sukel MP, Vissers PA,
Herings RM, Haak HR and van de Poll-Franse LV: Are metformin,
statin and aspirin use still associated with overall mortality
among colorectal cancer patients with diabetes if adjusted for one
another? Br J Cancer. 113:403–410. 2015. View Article : Google Scholar : PubMed/NCBI
|
42
|
Saber MM, Galal MA, Ain-Shoka AA and
Shouman SA: Combination of metformin and 5-aminosalicylic acid
cooperates to decrease proliferation and induce apoptosis in
colorectal cancer cell lines. BMC Cancer. 16:1262016. View Article : Google Scholar : PubMed/NCBI
|
43
|
Zhang Y, Guan M, Zheng Z, Zhang Q, Gao F
and Xue Y: Effects of metformin on CD133+ colorectal cancer cells
in diabetic patients. PLoS One. 8:e812642013. View Article : Google Scholar : PubMed/NCBI
|